Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats

Yong-fang XU; Na WU; Yue-xin HU; Yong-mei ZHAO; Shao-ding ZHENG; Ling WEI; Si-jia ZHENG; Jian-jun LIU

doi:10.12259/j.issn.2095-610X.S20210804

Volume 42 Issue 8

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(8): 17-22

Yong-fang XU, Na WU, Yue-xin HU, Yong-mei ZHAO, Shao-ding ZHENG, Ling WEI, Si-jia ZHENG, Jian-jun LIU. Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats[J]. Journal of Kunming Medical University, 2021, 42(8): 17-22. doi: 10.12259/j.issn.2095-610X.S20210804

Citation:

Yong-fang XU, Na WU, Yue-xin HU, Yong-mei ZHAO, Shao-ding ZHENG, Ling WEI, Si-jia ZHENG, Jian-jun LIU. Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats[J]. Journal of Kunming Medical University, 2021, 42(8): 17-22. doi: 10.12259/j.issn.2095-610X.S20210804

Citation:

Yong-fang XU, Na WU, Yue-xin HU, Yong-mei ZHAO, Shao-ding ZHENG, Ling WEI, Si-jia ZHENG, Jian-jun LIU. Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats[J]. Journal of Kunming Medical University, 2021, 42(8): 17-22. doi: 10.12259/j.issn.2095-610X.S20210804

PDF( 936 KB)

Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats

doi: 10.12259/j.issn.2095-610X.S20210804

1.
Dept. of Reproductive Medicine，The 1st People’s Hospital of Yunnan Province，Kunming Yunnan 650032
2.
School of Basic Medicine
3.
Incubation Center for Scientific and Technological Achievements
4.
Graduate School
5.
Biomedical Engineering Research Center & Yunnan Key Laboratory of Stem Cell and Regenerative Medicine； Kunming Medical University，Kunming Yunnan 650500，China

Received Date: 2021-06-11
Publish Date: 2021-08-25

Abstract

Abstract

Objective To establish a rat model of nonalcoholic fatty liver disease （NAFLD） and to explore the therapeutic effect of peroxidase activator receptor （PPAR） agonist GW7647 on rat NAFLD. Methods After the experimental animals were grouped, GW7647 was administered daily for 6 consecutive weeks. After intragastric administration, blood samples were collected for the detection of insulin resistance, blood lipid levels and liver injury-related biochemical indexes, and pathological tests （HE and oil red O staining） were performed on the liver tissues of the rats. Results After 6 weeks of treatment, GW7647 significantly reduced body weight, improved glucose tolerance and restored insulin sensitivity in NAFLD rats. Liver staining showed improvement in liver pathology and decreased accumulation of lipid droplets; serum cholesterol and triglyceride levels decreased; and serum AST and ALT levels showed improved liver injury （P < 0.05）. Conclusion PPARα agonist GW7647 has a therapeutic effect on NAFLD rats by reducing body weight, reducing liver fat accumulation, restoring insulin sensitivity, improving liver injury and reducing blood lipids.
- Peroxidase proliferator receptor α,
- Non-alcoholic fatty liver disease,
- High fat diet,
- PPARα agonist GW7647

FullText(HTML)

References(13)

References

[1]	Ng M,Fleming T,Robinson M,et al. Global,regional,and national prevalence of overweight and obesity in children and adults during 1980-2013:A systematic analysis for the global burden of disease study 2013[J]. Lancet (London,England),2014,384(9945):766-781. doi: 10.1016/S0140-6736(14)60460-8
[2]	Younossi Z,Koenig A,Abdelatif D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology (Baltimore,Md),2016,64(1):73-84. doi: 10.1002/hep.28431
[3]	Zobair M Younossi,Mary E Rinella,Arun J Sanyal,et al. From NAFLD to MAFLD:Implications of a premature change in terminology[J]. Hepatology,2021,73(3):1194-1198.
[4]	Dyson J,Anstee Q,McPherson S. Non-alcoholic fatty liver disease:A practical approach to diagnosis and staging[J]. Frontline Gastroenterology,2014,5(3):211-218. doi: 10.1136/flgastro-2013-100403
[5]	Puri P,Daita K,Joyce A,et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids[J]. Hepatology,2018,67(2):534-548. doi: 10.1002/hep.29359
[6]	Ezzaidi N,Zhang X,Coker O,et al. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer[J]. Cancer letters,2019,459(1):186-191.
[7]	Degasperi E,Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease[J]. The Lancet Gastroenterology & Hepatology,2016,1(2):156-164.
[8]	Madsen L,Guerre Millo M,Flindt EN,et al. Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance[J]. J Lipid Res,2002,43(5):742-750. doi: 10.1016/S0022-2275(20)30116-4
[9]	Wang X J,Malhi H. Nonalcoholic fatty liver disease[J]. Annals of Internal Medicine,2018,169(9):65-80. doi: 10.7326/AITC201811060
[10]	Chalasani N,Younossi Z. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the study of liver diseases[J]. Hepatology,2018,67(1):328-357. doi: 10.1002/hep.29367
[11]	Ruissen M M,Mak A L,Beuers U,et al. Non-alcoholic fatty liver disease:A multidisciplinary approach towards a cardiometabolic liver disease[J]. European Journal of Endocrinology,2020,183(3):57-73. doi: 10.1530/EJE-20-0065
[12]	Pawlak M,Lefebvre P,Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism,inflammation and fibrosis in non-alcoholic fatty liver disease[J]. Journal of Hepatology,2015,62(3):720-733. doi: 10.1016/j.jhep.2014.10.039
[13]	Huang K,Du M,Tan X,et al. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease[J]. Journal of Hepatology,2017,66(5):962-977. doi: 10.1016/j.jhep.2016.11.020

Relative Articles(20)

Relative Articles

[1]	Chengya MA, Jiang YANG, Xi CHEN, Xi XU, Pixuan YIN, Xin SHU, Hongyu PENG, Zhixiang FAN, Li LONG. Association between Myeloperoxidase-463G/A Gene Polymorphism and Essential Hypertension in Yi Nationality. Journal of Kunming Medical University, 2024, 45(4): 57-61. doi: 10.12259/j.issn.2095-610X.S20240408
[2]	Hang CHEN, Qi CUI, Minshan HUANG, Jianjun LIU, Lanqing MA. Research Progress of miRNA in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2024, 45(1): 1-7. doi: 10.12259/j.issn.2095-610X.S20240101
[3]	Yuanyuan LI, Yaxian SONG, Yushan XU, Xiaofu ZENG, Hui YUAN, Zhao XU, Yan JIANG. The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2024, 45(2): 77-84. doi: 10.12259/j.issn.2095-610X.S20240210
[4]	Chun LI, Qiong ZHOU, Cong MEI, Jie jie HUANG, Yi peng WANG, Song lan ZHOU, Qian ZHENG, Zhe TANG. Effect of Bifidobacterium trisporus on Intestinal Microbiota in the Mouse Model of Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2023, 44(10): 77-82. doi: 10.12259/j.issn.2095-610X.S20231022
[5]	Xuemin ZHANG, Yunfen TIAN. Role of Abnormal Bile Acid Metabolism in the Development of Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2023, 44(11): 164-169. doi: 10.12259/j.issn.2095-610X.S20231125
[6]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, 2023, 44(7): 148-155. doi: 10.12259/j.issn.2095-610X.S20230708
[7]	Cong LIU, Guishuai WU, Rui PU, Shude LI, Jianping TAO, Renfa ZHANG. EGCG Improves Myocardial Fibrosis Induced by High Fat and High Sugar Diet in Obese Rats by Inhibiting TGF-β1/Smads Signaling Pathway. Journal of Kunming Medical University, 2022, 43(5): 18-26. doi: 10.12259/j.issn.2095-610X.S20220506
[8]	Yongrui YANG, Liyuan WANG, Haiwen LI, Zhirong ZHAO, Rui PU, Guishuai WU, Shude LI. Scutellarin Ameliorates Liver Fibrosis in Nonalcoholic Fatty Liver Disease by Inhibiting NOX Expression. Journal of Kunming Medical University, 2022, 43(7): 38-45. doi: 10.12259/j.issn.2095-610X.S20220721
[9]	Sheng-hao LI, Jie DING, Qing-qing WANG, Si-qi LIU, Li-juan HUA, Jin-yu DUAN, Bao-li BO, An-rui DU, Guo-ji CHANG, Jun-yi LI. Influencing Factors of Moderate to Severe Liver Injury in Patients with Chronic Hepatitis B and NAFLD. Journal of Kunming Medical University, 2021, 42(7): 77-82. doi: 10.12259/j.issn.2095-610X.S20210712
[10]	Liang Wei Wei , Li Xiao Bo , Li Yan , Liu Hua , Wu Jun Zi . . Journal of Kunming Medical University, 2020, 41(07): 23-29.
[11]	Wang Bo , Xia Xian Song , Li Jin Tao , Duan Xiao Hua . . Journal of Kunming Medical University, 2020, 41(04): 11-17.
[12]	Ping-yan XUE, Yan JIANG, Yu-shan XU, Hui YUAN, Xuan LI, Ya-xian SONG, Hua LIU. Changes of Intestinal Flora in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2020, 41(11): 62-67. doi: 10.12259/j.issn.2095-610X.S20201120
[13]	Zhang Dan , Lv Jun Yan , Deng Yi , Zhou Bo , Luo Su Feng , Wang Jin Xiang , Wen Yu , Ying Yun Yan , Wen Dai Yan , Ma Lan Qing . . Journal of Kunming Medical University, 2020, 41(01): 11-17.
[14]	Zhu Wei Mei , Hua Peng , Luo Yu Chao , Yang Hong Ling , Li Ya Shan , Zhao Hong Yu . . Journal of Kunming Medical University, 2019, 40(02): 23-29.
[15]	Tian Wei . Liraglutide Improves The Symptoms of Non-alcoholic Fatty Liver Disease by Regulating Fatty Acid β-oxidation. Journal of Kunming Medical University,
[16]	Zhang Xin Wen , Zhang Yan , Hu Yan Xin , Pan Bao Long , Wang Ming Fang , Ma Run Mei . Establishment of Gestational Diabetes Rat Model Induced by High-fat Diet. Journal of Kunming Medical University, 2016, 37(11): 8-13.
[17]	Jiang Yan . . Journal of Kunming Medical University,
[18]	Zhang Yi . . Journal of Kunming Medical University,
[19]	Zhang Yuan . . Journal of Kunming Medical University,
[20]	He Hai Yu . . Journal of Kunming Medical University,